Effectiveness of Intravitreal Ranibizumab in Nonvitrectomized and Vitrectomized Eyes with Diabetic Macular Edema: A Two-Year Retrospective Analysis

Table 1

Baseline characteristics of the study groups.

	Total (n = 28)	Nonvitrectomized (n = 17)	Vitrectomized (n = 11)	value
Age (year)	59.0 ± 9.6	62.0 ± 9.0	55.0 ± 10.0	0.06
Female	14 (50.0%)	9 (52.9%)	5 (45.5%)	0.699
Hemoglobin A1c	7.6 ± 1.0	7.6 ± 1.1	7.7 ± 0.8	0.8
Time to IVR (month)†	15 ± 5	16 ± 5	13 ± 4	0.11

Continuous variables are presented as mean and standard deviation, and categorical variables are presented as number and percentage. ^†Duration from diagnosis of DM to IVR injections, Student’s t-test, and chi-square test. DM indicates diabetes mellitus; IVR, intravitreal ranibizumab.